The global physiotherapy equipment market is projected to reach USD 24.5 billion by 2027 from USD 18.4 billion in 2022, at a CAGR of 6.0% during the forecast period. The growing demand for rehabilitative care, the growing incidence of sports injuries, degenerative joint disorders, and cerebrovascular disease, and rapidly growing geriatric population; the subsequent increase in the global prevalence of chronic diseases is driving the growth of market.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65250228

In this report, the physiotherapy equipment market is segmented on the basis of product, application, end user, and region. Based on product, the physiotherapy equipment market is divided into two major segments, namely, equipment and accessories. The equipment segment accounted for the largest share of the physiotherapy equipment market in 2021. Market growth is largely driven by factors such as the rapidly aging population, the growing adoption of healthier lifestyle habits, as well as the increasing incidence of injuries and chronic diseases. The equipment segment is further segmented into electrotherapy equipment, ultrasound equipment, exercise therapy equipment, heat therapy equipment, cryotherapy equipment, combination therapy equipment, continuous passive motion therapy equipment, shockwave therapy equipment, laser therapy equipment, magnetic pressure therapy equipment, traction therapy, and other physiotherapy equipment (hydrotherapy and vacuum therapy). Electrotherapy equipment dominates the market with a share of about 25.6% in 2021, owing to their significant use in the treatment of musculoskeletal conditions with minimal/no side effects.

Based on the application, the physiotherapy equipment market is segmented into musculoskeletal applications, neurological applications, cardiovascular and pulmonary applications, pediatric applications, gynecological applications, and other applications (including sports and palliative care). In 2021, the musculoskeletal applications segment accounted for the largest share of physiotherapy equipment market, which can be attributed to the rising incidence of musculoskeletal disorders, growth in the geriatric population, and the increasing number of accidents.

Based on End User, the physiotherapy equipment market is segmented into physiotherapy & rehabilitation centers, hospitals, home care settings, physician offices, and other end users (community health centers and elderly care facilities). In 2021, physiotherapy & rehabilitation centers accounted for the largest share of the physiotherapy equipment market. This can primarily be attributed to the wide usage of physiotherapy equipment in these centers and the increased availability of specialized physiotherapists in such facilities.

In 2021, Europe accounted for the largest share of the global physiotherapy equipment market. The large share of this regional segment can be attributed to the rising geriatric population, increasing inclination for active lifestyles, the penetration of physiotherapy services, and favorable healthcare reforms. The Asia Pacific market is projected to register the highest CAGR during the forecast period. Market growth in the Asia Pacific is attributed to the growth in emerging markets such as China and India, that are expected to present significant growth opportunities for the major stakeholders in the physiotherapy market. Additionally, increasing healthcare awareness and growing number of healthcare facilities in Asian countries are also the key factors supporting the market growth.

Major Companies:

Colfax Corp. (US), BTL Industries (UK), Performance Health (US), ITO Co., Ltd. (Japan), Enraf-Nonius B.V. (Netherlands), Dynatronics Corporation (US), Mectronic Medicale (Italy), EMS Physio Ltd. (UK), Whitehall Manufacturing (US), Zimmer MedizinSysteme GmbH (Germany), Zynex Inc, (US), Richmar (US), Life Care Systems (India), Storz Medical AG (Germany), Mettler Electronics Corp (US), Algeos (UK), Gymna (Belgium), Astar (Poland), HMS Medical Systems (India), Embitron s.r.o (Czech Republic), Proxomed (Germany), Tecnobody (Italy), Johari Digitals (India), Power Medic (Denmark), and CoolSystems Inc. (US)

Recent Developments of Physiotherapy Equipment Industry

In February 2022, Colfax Corp (US), announced the renewal of the partnership with Professional Football Athletic Trainer Society (PFATS, US), that allowed the company to endorse and recommend its products to certified athletic trainers.

In January 2022, BTL Industries (UK) acquired Schepp MedTech (US). This acquisition was carried out for robots to enhance BTL’s already very complex physiotherapy product portfolio.

In January 2022, Zynex, Inc. (US) announced the launch of Post-operative and OA (Osteoarthritis) knee braces. The Knee braces can limit the wear and tear on the affected joint, enabling inflammation to settle and reduce pain/degeneration of the affected knee joint and thereby delaying or minimizing the need for surgery.

In January 2021, Dynatronic Corporation (US) launched a new bariatric stand-in table with a motorized patient lift and an H-brace treatment table.

The multiplex assays market is valued at an estimated USD 3.5 billion in 2022 and is projected to reach USD 5.3 billion by 2027, at a CAGR of 8.8% during the forecast period. The increasing applications of companion diagnostics in drug development and the significance of multiplex assays in companion diagnostics are expected to drive the multiplex assays market.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=61593314

Based on product & service, the multiplex assays market is segmented into three broad categories, namely, consumables, instruments, and software & services. In 2022, the consumables segment accounted for the largest share of the market. The availability of a wide range of reagents and kits and increasing use of assays in different oncology therapeutic treatments are some of the major factors driving the growth of the consumables market.

On the basis of type, the multiplex assays market is segmented into protein, nucleic acid, and cell-based multiplex assays. The nucleic acid multiplex assays segment is further divided into planar, bead-based, and other nucleic acid multiplex assays. The protein multiplex assays segment is further categorized into planar, bead-based, and other protein multiplex assays. The protein multiplex assays segment accounted for the largest share of the global multiplex assays market in 2022. Protein multiplex assays are preferred over traditional protein analysis tools mainly due to their distinct advantages, such as the simultaneous profiling of multiple analytes using smaller sample amounts. Such distinct features make protein multiplex assays more suitable for research applications where samples are scarce and valuable resources. This is expected to support market growth of this segment.

Based on technology, the multiplex assays market is divided into flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, and other technologies. In 2022, the flow cytometry segment accounted for the largest share of the global multiplex assays market. Its wide applications in protein expression, RNA, and cell health status makes it the largest market segment.

Based on applications, the multiplex assays market is segmented into research & development (drug discovery & development and biomarker discovery & validation) and clinical diagnostics (infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, metabolism & endocrinology disorders, and other diseases). The research & development application segment is expected to account for the largest share of the multiplex assays market in 2022. Multiplex assays are easy to use and are associated with reduced turnaround times, owing to which they are preferred for research & development applications as compared to conventional single plex assays.

The global multiplex assays market has been segmented into five major regions— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). In 2022, North America accounted for the largest share of the global multiplex assays market. The large share of North America in the global market is attributed to factors such as the rising amount of government funding for R&D in multiplex assays; an increasing number of seminars and workshops about emerging technologies in the domain of multiplex assays; the growing adoption of companion diagnostics for personalized treatment; and the rising need for effective analytical platforms to reduce operational costs.

Major Companies:

Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), QIAGEN N.V. (Netherlands), Abcam plc (UK), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Quanterix (US), Bio-Techne (US), MESO SCALE DIAGNOSTICS, LLC (US), Randox Laboratories Ltd. (UK), Olink (Sweden), Seegene Inc. (South Korea), Siemens Healthcare AG (Germany), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Promega Corporation (US), Enzo Biochem Inc. (US), Cayman Chemical (US), Boster Biological Technology (US), Antigenix America, Inc. (US), Quansys Biosciences Inc. (US), and RayBiotech Life, Inc. (US).

According to the new market research report “Behavioural/Mental Health Software Market by Component (Services, Software), Delivery (Subscription, Ownership), Functionality (Clinical, EHR, CDS, Telehealth, RCM, BI, Administrative, Financial), End User (Hospitals, Clinics) – Global Forecasts to 2026″, published by MarketsandMarkets™, the global Behavioral Health Software Market is expected to reach USD 4.9 billion by 2026 from USD 2.0 billion in 2021, at a CAGR of 19.6% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=45953340

The major factors driving the growth of behavioral health software market are the increasing adoption of behavioral health software, availability of government funding, government initiatives to encourage EHR adoption in behavioral health organizations, favorable behavioral health reforms in the US, and high demand for mental health services amidst provider shortage. On the other hand, data privacy concerns and a shortage of HCIT personnel are expected to restrain the growth of this market.

Based on components, the mental health software market is segmented into software and support services. The support services segment is expected to account for the largest share of the market in 2021. The recurring requirement of support services (such as software upgrades and maintenance) is the major factor supporting its growth.

Based on end users, the behavioral health software market has been segmented into community clinics, hospitals, and private practices. In 2021, the community clinics segment is expected to account for the largest share. Growing government initiatives to support these facilities and growing patient preference for community clinics are likely to drive behavioral health software adoption in this segment.

On the basis of region, the behavioral health software market has been segmented into four major regions, namely, North America, Europe, the Asia Pacific and rest of the world. In 2021, North America is expected to dominate the market followed by Europe. The large share of this geographical segment is attributed to factors such as the growing number of people requiring behavioral health services, behavioral health reforms in the US, and government funding for behavioral health services in the region.

Major players operating in the behavioral health software market include Advanced Data Systems (US), AdvancedMD (US), Cerner (US), Compulink (US), Core Solutions (US), Credible Behavioral Health (US), Kareo (US), Meditab Software (US), Mindlinc (US), Netsmart (US), Nextgen Healthcare (US, Qualifacts (US), The Echo Group (US), Valant (US), Welligent (US), Cure MD(US), Epic systems corporations (US), Accumedic (US), Mediware(US), Allscripts (US)

Recent Developments:

In July 2020, Cerner(US) collaborated with Nuance Communications, Inc. (US). This long-standing collaboration aimed to integrate Nuance’s virtual assistant technology into Cerner Millennium.

In April 2020, Netsmart (US) partnered with The California Department of Veterans Affairs (CalVet, US). This partnership helped CalVet to implement Netsmart’s person-centered EHR platform, myUnity, to provide enhanced clinical and operational effectiveness in its delivery of day-to-day care to its residents

In February 2021, Netsmart acquired GPM, a North Carolina-based Software-as-a-Service technology and services company. This will help Netsmart’s CareFabric platform to deliver interoperable data sharing between long-term care facilities and providers.

The global Cartilage Repair/Cartilage Regeneration market is projected to reach USD 2.8 Billion by 2028 from USD 1.3 Billion in 2023, at a CAGR of 17.2% during the forecast period. Growth in the Cartilage Repair/Cartilage Regeneration market is mainly driven by the Increasing incidence of osteoarthritis, Increasing research funding and investments and the Rising number of sports and accident-related orthopedic injuries expected to grow the market demand Cartilage Repair/Cartilage Regeneration market during the forecast period.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37493272

Based on the treatment modality, the cartilage repair/cartilage regeneration market is divided into two categories which are cell-based including chondrocyte transplantation, growth factors, and stem cells and non-cell-based like tissue scaffolds and cell-free composites. In 2022, the cell-based segment had the largest share in the treatment modality segment which is mainly due to advancements in stem cell- therapies used for cartilage repair.

Based on the Application site, the cartilage repair/cartilage regeneration market is categorized into knees, hips, ankles & feet, and other application sites like nose and shoulder. In 2022, The knee segment holds the largest share of the cartilage repair/cartilage regeneration market. The factors responsible for the growth of the segment are the increasing number of knee arthroscopy procedures and the rising incidence of knee osteoarthritis cases globally.

Based on the Application, the global cartilage repair/cartilage regeneration market is broadly segmented into hyaline cartilage and fibrocartilage. The hyaline cartilage segment accounted for the largest share of the cartilage repair and regeneration market in 2022. Hyaline cartilage is expected to grow highest in the upcoming years due to the increasing number of cartilage repair procedures performed worldwide is the major factor driving the growth of this application segment. Technological advancements, product developments and launches, and growing partnerships between key market players and hospitals are also supporting market growth.

Based on the region segmentation, the cartilage repair/cartilage regeneration market is divided into North America, Europe, Asia Pacific, and the Rest of the World. North America holds the largest share and expects to dominate the cartilage repair/cartilage regeneration market. Growth in the North American market is mainly driven by the rising growth opportunities in emerging economies and growing number of contracts and agreements between market players.

Major Companies:

Smith+Nephew (UK), DePuy Synthes (Johnson & Johnson) (US), Zimmer Biomet Holdings, Inc. (US), Stryker Corporation (US), Vericel Corporation (US), B. Braun Melsungen AG (US), Anika Therapeutics (US), CONMED Corporation (US), MEDIPOST (South Korea), RTI Surgical (US), Arthrex, Inc. (US), Regrow Biosciences (India), Geistlich Pharma AG (Switzerland), AlloSource (US), Orthocell Ltd, (Australia), Matricel GmbH (Germany), CartiHeal, Inc. (Israel), Regentis Biomaterials (Israel), Theracell Advanced Biotechnology (Greece), and LifeNet Health (US)

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships of the leading players, the competitive landscape of the cartilage repair/cartilage regeneration market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are:

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the cartilage repair/cartilage regeneration market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was collected after acquiring knowledge about the cartilage repair/cartilage regeneration market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as Hospitals) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing, and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific and Rest of the world. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

The global antimicrobial resistance surveillance market is projected to reach USD 7.7 billion by 2028 from USD 5.9 billion in 2023, at a CAGR of 5.6% during the forecast period. Growth in this market is majorly driven by factors such as the growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies and growing government initiatives to combat antimicrobial-resistance species.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21323165

Antimicrobial Resistance Surveillance Market by Solution (Kits, System, Surveillance Software, Service), Application (Clinical Diagnostics, Public Health Surveillance), End User (Hospitals, Clinics, Academic, Research Institutes) – Global Forecast to 2028

The prominent players in this market are Becton, Dickinson and Company (US), Biomerieux (France), Thermo Fisher Scientific (US), Danaher (US), Luminex Corporation (US), Bruker (US), Merck KgaA (Germany), Bio-Rad (US), Qiagen (Germany), Abbott Laboratories (US), Roche Diagnostics (Switzerland), OpGen, Inc. (US), Wolters Kluwer N.V. (US), Lumed (US), BioSpace (US), Cepheid (US), Accelerate Diagnostics, Inc. (US), Liofilchem S.r.l. (Italy), Alifax S.r.l. (Italy), and Bioanalyse (Turkey).

The global market for antimicrobial resistance surveillance is categorized into different solutions, including diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the dominant portion of this market is held by the diagnostic kits segment. This prominence is mainly a result of the growing need for swift and precise tools for identifying antimicrobial resistance. These diagnostic kits play a crucial role in identifying the existence of bacteria resistant to antimicrobial agents within clinical samples like blood, urine, and respiratory secretions.

Categorized by its applications, the global market for antimicrobial resistance surveillance is divided into clinical diagnostics, public health surveillance, and other uses. For the year 2023, it is projected that the clinical diagnostics segment will hold the most significant portion of the global antimicrobial resistance surveillance market. This expansion within the segment is linked to several factors, including the escalating occurrence of antimicrobial resistance, the imperative to enhance patient outcomes, the utility in determining bacteria’s susceptibility to diverse antimicrobial agents. This information is crucial for healthcare providers to make well-informed choices regarding the treatment of patients afflicted with infections resistant to antimicrobial treatments.

Categorized by their end users, the global market for antimicrobial resistance surveillance is divided into hospitals & clinics, research and academic institutes, and other entities. For the year 2023, it is anticipated that the hospitals & clinics segment will hold the most substantial portion of the global antimicrobial resistance surveillance market. The prevalence of this segment can be attributed to its crucial role at the frontline of patient care, infection management, and data generation. Furthermore, hospitals & clinics are obligated to undertake surveillance of antimicrobial resistance as an integral part of their operations.

Categorized by geographical regions, the antimicrobial resistance surveillance market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. In the year 2023, it is projected that the North American sector of the antimicrobial resistance surveillance market will hold the most significant portion. This prominence can be ascribed to several factors, including the existence of prominent market participants, heightened consciousness regarding antimicrobial resistance surveillance, and a robust regulatory framework.

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

The diagnostic imaging services market is projected to reach USD 702.6 billion by 2027 from USD 549.0 billion in 2022, at a CAGR of 5.1% during the forecast period. Factors such as increasing prevalance of chronic diseases, rapidly growing geriatric population, technological adavancements in imaging modalities, and rising  demand for early diagnosis of diseases are anticipated to propel the growth of market during the forecast period.

Howerevr,  rising cost of diagnostic imaging equiments, shortage of skilled workforce and unfavorable reimbusment structure of out patient imaging facilities in lower income countries are are anticipated to hamper the overall growth of the market.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17157849

Diagnostic Imaging Services Market Size, Growth by Procedure (MRI, Ultrasound, CT, X-RAY, Nuclear Imaging, Mammography), Application (OB/Gyn, Pelvic/Abdomen, Cardiology, Oncology, Neurology), Technology, User (Hospitals, Diagnostic Centers) – Global Forecast to 2027

The diagnostic imaging services market is segmented on application into general radiography, dentistry, and other X-ray applications. The general radiography segment will dominate the market during the forecast period. The large share of this application segment can be attributed to the rising prevalence of lung diseases globally and the increasing use of 3D X-ray imaging technogy in applications for chest, orthopedic & rheumatological, and cardiovascular imaging

Based on end users, the diagnostic imaging services market is segmented into hospitals, diagnostic imaging centers, ambulatory care centers, and research & academia. In 2021, hospitals were the largest diagnostic imaging services market end users. The large share of the hospitals segment can be attributed to growing adoption of 3D imging technology, increasing adoption of minimally invasive procedures and ongoing collaboration with market players to adopt diagnostic imaging solutions. In April 2022, Siemens Healthineers (Germany) collaborated with Oulu University Hospital (Finland) to expand radiology solutions through supplying, installing, and maintaining medical imaging technology and software training in Finland.

Based on region, the diagnostic imaging services market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest share of the diagnostic imaging services market in 2021. The growth of the North American market is primarily driven by the  strong foothold of key players in the region offering wide range of diagnostic imaging services. increased collbartion among imaging service providers and  diagnostic centers , rapid adoption of highly adavanced imaging technology, and rising volume of imaging scans performed anully in the region.

The major player in the market includes RadNet, Inc. (US), Sonic Healthcare (Australia), Akumin Inc. (US), Healius Limited (Australia), RAYUS Radiology (US), Dignity Health (US), Novant Health (US), Alliance Medical (UK), InHealth Group (UK), Apex Radiology (Australia), Concord Medical Services Holdings Limited (China), Unilabs (Switzerland), Affidea (Netherlands), I-MED Radiology Network (Australia), Capitol Imaging Services (US), SimonMed (US), among others

Recent Developments:

• In 2022, Radnet, Inc. acquired Quantib and Aidence with an aim to expand its cancer screening portfolio for breast, prostate, and lung cancers through the integration of AI technology.
• In 2021 , Sonic Healthcare announced the acquisition of Canberra Imaging Group (Australia) to helped strengthen Sonic Healthcare’s geographic footprint in the Australian diagnostic imaging services market.
• In 2021, Akumin Inc. acquired Alliance Healthcare to enhance its diagnostic imaging service portfolio.

The global optometry equipment market is valued at an estimated USD 4.5 billion in 2024 and is projected to reach USD 6.1 billion by 2029, at a CAGR of 6.4% during the forecast period. The three main factors propelling the growth of the optometry equipment market are the aging population, the rise in eye illnesses, and the rising cost of healthcare in emerging nations.

The retina and glaucoma examination products, general examination products, and cornea and cataract examination products comprise the type-based segments of the worldwide optometry equipment market. During the projected period, the optometry equipment market, with its focus on retina and glaucoma examination items, is anticipated to have the greatest growth rate and market share. This segment is growing at a significant rate mostly because to an increase in glaucoma and retinal illnesses.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14475790

Based on application, the optometry equipment market is divided into categories such as general examination, cataract, glaucoma, age-related macular degeneration, and other applications. Over the course of the projection period, the general examination category is anticipated to have a larger market share. In the upcoming years, factors including the growing prevalence of eye illnesses and the increased awareness of eye care are anticipated to fuel market expansion.

Hospitals, eye clinics, and other end users comprise the end user segment of the optometry equipment market. In terms of worldwide market share for optometry equipment in 2023, the clinics sector led. The segment’s market share is influenced by a large patient pool that is treated in clinics, an increasing number of private clinics and practitioners in emerging countries, and an increase in the prevalence of visual impairments among the elderly.

The optometry equipment market is segmented into four major regions—North America, Europe, the Asia Pacific and Rest of the World (Latin America, the Middle East & Africa and GCC Countries). Over the course of the forecast period, the Asia Pacific market is anticipated to develop at the greatest CAGR. The rising incidence of ocular illnesses, rising healthcare spending in certain APAC nations, and the existence of high-growing markets in the area are all factors contributing to this market’s rise. The positive regulatory climate in this area is also anticipated to fuel market expansion.

Carl Zeiss Meditec AG (Germany), Alcon (Switzerland), EssilorLuxottica (France), Topcon Corporation (Japan), Bausch Health Companies Inc. (Canada), NIDEK Co. Ltd. (Japan), Canon Inc. (Japan), Johnson and Johnson (US), HEINE Optotechnik (Germany), Revenio Group PLC (Finland), Haag-Streit Group (Switzerland), Heidelberg Engineering (Germany), Luneau Technology (France), Escalon Medical (US), Keeler Ltd. (UK), Reichert Technologies (US), Oculus Inc. (US), Kowa American Corporation (US), Ziemer Ophthalmic Systems AG (Switzerland), Huvitz (South Korea), Neitz Instruments Co. Ltd. (Japan), Rexxam Co. Ltd. (Japan), Rudolf-Riester GmbH (Germany), FREY (Poland), and Yeasn (China)

Recent Developments of Optometry Equipment Industry:

• In August 2023, Carl Zeiss launched the ZEISS trifocal technology on a glistening-free hydrophobic C-loop platform and a fully preloaded injector for safe and reliable implantation.
• In March 2022, Topcon Corporation launched SOLOS, an automatic lens analyzer that enables advanced, accurate, and efficient lens analysis at the touch of a button.
• In September 2023, Bauch + Lomb acquired XIIDRA to grow in the prescription dry eyes segment.
• In January 2023Bausch + Lomb acquired AcuFocus to expand its cataract surgical portfolio.

The global lab automation market is projected to reach USD 7.1 billion by 2028 from USD 5.1 billion in 2022, growing at a CAGR of 5.8% during the forecast period. The growth of this market is primarily driven by the increasing investments and for the technological advancements. Robots can carry out repetitive operations like labeling by hand and handling microplates, while motorised pipettes and syringes can handle liquid handling. Additionally, lab automation software can help you save time by making it simple to standardise and manage your workflow. increasing surgical procedures due to growing burden of chronic diseases.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1158

Based on products, the lab automation market is segmented into automated workstations, off-the-shelf automated work cells, software, robotic systems, automated storage & retrieval systems, and lab automation equipment. Automated workstations are expected to dominate the lab automation market during the forecast period. Workstations reduced costs, ensuring efficiency, and improve turnaround time are key factors driving the market growth.

Based on applications, the lab automation market is segmented into drug discovery, diagnostics, genomics, proteomics, microbiology, and other applications. The drug discovery application segment is estimated to hold the largest market share of the lab automation market during the forecast period. The large share of this segment can be attributed to the increasing investments by pharmaceutical and biotechnology companies.

The lab automation market covers five key geographies—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The market in North America accounted for the largest share of market in 2022. The large share of the market can be attributed to the strong presence of major pharmaceutical companies and the large number of life science research studies conducted in the region. Asia Pacific is expected to account for the second-largest share of the global lab automation market. Investments by both public and non-public sectors to upgrade laboratories, the rising number of diagnostics procedures, the increasing number of laboratories hospital and diagnostic centres, and the increasing prevalence of non-communicable diseases in the US In Canada.

Thermo Fisher Scientific (US), Tecan Group (Switzerland), Danaher Corporation (US), Agilent Technologies (US), F. Hoffmann-La Roche (Switzerland), PerkinElmer (US), Eppendorf (Germany), Becton, Dickinson and Company (US), Waters Corporation (US), Siemens Healthineers (Germany), Abbott Laboratories (US), bioMérieux (France), Endress+Hauser Group (Switzerland), Hamilton Company (US), and Hudson Robotics (US) among others

Recent Developments of Lab Automation Industry

• In January 2023, Agilent Technologies, acquired Avida Biomed, an early-stage life science firm that creates high-performance target-enrichment procedures with distinctive features for clinical researchers using next-generation sequencing methods to investigate cancer.
• In November 2022, F. Hoffmann-La Roche Ltd. collaborated with PathAI for artificial intelligence-based digital pathology applications for improved patient care.
• In November 2022, PerkinElmer launched ready-to-use adeno-associated virus vector (AAV) detection kits to support researchers working on gene therapies.
• In August 2021, Becton Dickinson AG launched a fully automated high-throughput molecular diagnostic platform for laboratories in the US.

The epigenetics market is projected to reach USD 4.3 Billion by 2028 from USD 1.8 Billion in 2023, at a CAGR of 18.3%  during the forecast period. Market growth is largely driven growing investment in research & development and rising demand for epigenetic-based therapeutics.

Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology) – Global Forecast to 2028

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896

Based on product & service, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The kits & reagents segment is further segmented into antibodies ChiP-sequencing kits, whole genome amplification kits, bisulfite conversion kits, 5-HMC and 5-MC analysis kits, histones, and other kits & reagents. The kits & reagents segment accounted for the largest share of the market in 2022. The highest share of the segment is owing broadening applications of chromatin immunoprecipitation (ChIP) in research studies associated with epigenetic regulatory systems and growing demand for DNA modification enzymes and histone modification enzymes.

Based on method, the epigenetics market is segmented into DNA methylation, histone modifications, and other methods. In 2022, the DNA methylation segment accounted for the largest share of the epigenetics market. The largest share can be attributed to expanding use of DNA methylation approaches across non-oncology applications. Additionally increase in R&D to explore the role of histone modifications in oncology applications contributes to the highest CAGR recorded by the histone modifications segment in the epigenetics market.

Based on technique, the epigenetics market is divided into NGS, PCR & qPCR, mass, spectrometry, sonication, and other techniques. The NGS segment accounted for the largest share of the market in 2022. Rising demand for NGS solutions across epigenetic and mutational research studies is serving as the driving factor for growth of NGS segment.

Based on application, the epigenetics market is segmented oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, and other applications. In 2022 oncology segment accounted for the larger share of the market. The higher share of this segment is due to the growing demand for epigenetic processes such as DNA methylation and histone modification in the development of novel cancer therapeutic candidates.

Based on end user, the global epigenetics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies and hospitals & clinics. In 2022, academic & research institutes segment accounted for the largest share of the market. The key factor of driving the growth of the this market segment can be attributed to the adoption of epigenetics products across different research sectors including university laboratories and government research institutions.

Based on the region, the epigenetics market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. In 2022, North America accounted for the largest share of the epigenetics market, Europe is the second largest region in 2022. The growth factors can be attributed to to the robust network of epigenetic product manufacturers, and increasing NGS-based research.

The Asia Pacific market is expected to register the highest CAGR of 19.1% during the forecast period. In 2022, the growth of the market is driven by the growing pharmaceutical industry, implementation of favorable government policies and the low cost of epigenetic consumables in this region.

The epigenetics market is moderately consolidated, with a small number of players competing for market shares.  Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode SA (US), F. Hoffmann-La Roche Ltd (Switzerland) and Epigentek Group Inc. (US) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, and agreements, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

The global neuromodulation market is projected to reach USD 11.0 billion by 2028 from USD  6.2 billion in 2023, at a CAGR of 12.0% during the forecast period. The neuromodulation market is driven by increasing focus on the development of advanced neuromodulation and neurostimulation technologies, rising prevalence of neurological disorders and nerve injuries, government support for research on neurological disorders, availability of reimbursement of neuromodulation devices, collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices.

The rising incidences of neurological diseases across the globe have increased significantly. Neuromodulation is used to treat and improve the quality of life of individuals suffering from chronic illness.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=921

Neuromodulation Market by Type (Internal (Spinal Cord Stimulation, Deep Brain Stimulation), External (Transcranial Magnetic Stimulation), Application (Tremor, Epilepsy, Parkinson’s Disease, Depression, Gastroparesis), and Region – Global Forecast to 2028

On the basis of type, neuromodulation market is segmented into internal neuromodulation and external neuromodulation. In 2022, internal neuromodulation accounted for the largest share of the global neuromodulation market. This growth can be mainly attributed to reduction of post surgical complications, reduced hospitalizations, and long term cost savings associated with internal neuromodulation devices.

The internal neuromodulation market is further categorized into sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation,  deep brain stimulation, and gastric electrical stimulation. The spinal cord stimulation segment accounted for the largest share of the neuromodulation market in 2022, owing to the increasing number of people suffering from failed back surgery syndrome, ischemia, and chronic pain as well as the favorable reimbursement scenario for spinal cord stimulation.

The external neuromodulation market is segmented into transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS), and respiratory electrical stimulation (RES). In 2022, transcutaneous electrical nerve stimulation will dominate the external neuromodulation market. This is mainly due to the higher prevalence of depression, its chronic and recurrent nature, and the life-shortening effects of this disease, which have created a demand for TENS therapy.

Based on application, the neuromodulation market has been segmented into vagus nerve stimulation,  spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, gastric electrical stimulation, transcutaneous electrical nerve stimulation, and transcranial magnetic stimulation. The neuromodulation market for Spinal cord stimulation by application is further segmented into chronic pain, failed back syndrome and ischemia. In 2022, chronic pain applications dominated neuromodulation market. This growth can mainly attributed to the growing aging population and subsequent increase in prevalence of neurological disorders.

The neuromodulation market is categorized into four major regions: North America, Europe, the Asia Pacific, and Rest of the World. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period, primarily due to the increasing public and private investments, increasing incidence of neurological disorders and ongoing research.

Major Players:

Medtronic (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), LivaNova (UK), NeuroPace (US), Neuronetics (US), Helius Medical Technologies (US), Renishaw (UK), GTX Medical (Netherlands), Bioinduction (UK), Axonics (US), Nevro Corporation (US), Nalu Medical (US), Aleva Neurotherapeutics (Switzerland), GiMer Medical (Taiwan), Magtism (UK), NeuroSigma (US), BioWaveGo USA (US), Synapse Biomedical (US), BIOTRONIK (Germany), Theranica Bio-Electronics (Israel), MicroTransponder (US), Soterix Medical (US), Saluda Medical (US), Electrocore, Inc. (US) and tVNS Technologies (Germany)

Recent Developments of Neuromodulation Industry:

• In 2023, Medtronic (Ireland) received CE (Conformité Européenne) Mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS).
• In 2023, Boston Scientific Corporation (US) received the US FDA approval for the Vercise Neural Navigator 5 Software/ It is a part of the Vercise Genus Deep Brain Stimulation (DBS) Systems.
• In 2023, Boston Scientific Corporation (US) entered into an agreement to acquire Relievant Medsystems, Inc. (US) to expand its neuromodulation portfolio to provide more treatment options for people living with chronic low back pain.
• In 2022, Medtronic (Ireland) received FDA approval for InterStim X System, which is a next-generation personalized sacral nerve stimulation therapy used for bladder and bowel control.